Form 4: Outset Medical GC Sells Shares for Tax Obligations

Outset Medical's General Counsel, John L. Brottem, sold 383 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• John L. Brottem, General Counsel of Outset Medical, Inc. (OM), reported a sale of company common stock.
• The transaction occurred on August 15, 2025.
• 383 shares of common stock were sold at a price of $12.88 per share.
• The sale was a "sell to cover" transaction to satisfy tax withholding obligations.
• This sale was in connection with the vesting of 748 shares of Common Stock underlying Restricted Stock Units (RSUs).
• The RSUs were granted on January 6, 2023, and January 12, 2024.
• Following the transaction, Mr. Brottem beneficially owns 46,883 shares of common stock directly.
• The sale was not a discretionary trade by the reporting person.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary "sell to cover" for tax purposes, which is a routine event and does not reflect positive or negative sentiment about the company's future prospects.

Positives

• The sale was non-discretionary, specifically to cover tax withholding obligations from RSU vesting, indicating it was not a voluntary divestment based on market outlook.

Negatives

• No direct negatives identified as the sale was non-discretionary and for tax purposes.

Future Outlook

NA

Management Comments

• Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 748 shares of Common Stock underlying RSUs granted to the reporting person on January 6, 2023, and January 12, 2024.
• This sale was made to satisfy tax withholding obligations through a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries when equity compensation vests. It does not provide insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The "sell to cover" transaction is a standard practice for executives and employees receiving equity compensation across all industries, including medical technology. It aligns with typical mechanisms for managing tax liabilities upon RSU vesting and does not indicate a deviation from industry norms.

Stakeholder Impact

• Minimal direct impact on shareholders as the sale of 383 shares is a small, non-discretionary transaction for tax purposes, not indicative of a change in management's confidence or a significant dilution event.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary "sell to cover" transaction by an insider to satisfy tax obligations related to RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or the insider's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a "hold" stance is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Outset Medical, OM, Form 4, Insider Transaction, Stock Sale, General Counsel, RSU, Restricted Stock Units, Tax Withholding, Sell to Cover